Hi all,
As we are now in revenue phase, it's great to have a revenue thread (thanks to
@Thegun96) where we can post our forecasts and discussions. I have previously posted an estimate but I thought I'll post my comprehensive estimate that includes SleepCheck, Coviu and Phenix for FY2021.
Here's my assumptions:- Tests are at the lowest agreed price, which is $5 per test;
- Coviu has stated that they are now doing 25,000 consultations a day and 50% is respiratory related (i.e.12,500 a day). However, I have some reservation about the number and used a very conservative number of only 5000 a day;
- It's unclear how many consultations Phenix are doing each day and I had to take a wild guess - 1000 a day (20% of Coviu);
- Initial uptake of 10%;
- Quarterly growth of uptake of 5%;
- Quarterly increase in no.consultation of 10%;
From my calculations, I'm expecting our first quarterly revenue to be around
$300k. However, given both Coviu & Phenix wouldn't be online until next week, perhaps it'll be somewhere around
$250k-$275k. Hopefully by the end of this FY, our quarterly revenue can be in the ball park of around
$1.1m+.
Again, this is my very, very conservative estimate
using the lowest agreed cost of $5 and
heavy discount in terms of uptake %. This is also only from our current 3 revenue streams, excluding any other potential partners that could be onboard within this FY. My estimate for SleepCheck and is a complete wild guess and happy for anyone to provide some guidance.
Feel free to post your own estimates or your thought on my guess whether you think this is too high/low and why.
This is gonna be a very exciting year for RAP and hoping we can see some unexpected deals in the near future
GLTAH and DYOR
(20min delay)